Human TNFRSF4 / OX40 / CD134 Protein (His Tag)
ACT35,CD134,IMD16,OX40,TXGP1L
- 100ug (NPP1678) Please inquiry
| Catalog Number | P10481-H08H |
|---|---|
| Organism Species | Human |
| Host | Human Cells |
| Synonyms | ACT35,CD134,IMD16,OX40,TXGP1L |
| Molecular Weight | The recombinant human TNFRSF4 consists of 199 amino acids after removal of the signal peptide and has a predicted molecular mass of 21.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh TNFRSF4 is approximately 40-45 kDa due to glycosylation. |
| predicted N | Leu 29 |
| SDS-PAGE |  |
| Purity | > 90 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the extracellular domain (Met 1-Ala 216) of human TNFRSF4 (NP_003318.1) was expressed, fused with a polyhistidine tag at the C-terminus. |
| Bio-activity | 1. Measured by its binding ability in a functional ELISA. 2. Immobilized human TNFRSF4-his (P 10481-H08H) at 2 μg/mL (100 μl/well) can bind human TNFSF4/mFc (cat: 13127-H04H), The EC50 of human TNFSF4/mFc is 29 ng/mL. |
| Research Area | Immunology |Cluster of Differentiation (CD) |B Cell CD Antigen |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease. |
| Reference |